Literature DB >> 7007221

BCG, Corynebacterium parvum or Mycobacterium leprae added to cultures of BCG-primed mouse spleen cells cause an enhanced primary antibody response in vitro.

C A Brown, I N Brown, V S Sljivić.   

Abstract

A few weeks after mice were injected i.v. with 10(8) live Mycobacterium bovis, BCG, the antibody response of their spleen cells to SRBC in vitro was comparable with the response of cells from untreated mice. Addition of BCG organisms to the culture vessels resulted in enhanced antibody-forming cell (AFC) responses by the primed cells but not by the cells from the untreated mice. No evidence was found for a direct stimulation of B cells and cell depletion experiments suggested macrophages were directly involved. BCG added to the cultures up to 68 h after they were set up, but not later, still caused enhancement. No enhancement was found when DNP-Ficoll was used as antigen. The ability to stimulate the anti-SRBC response was not restricted to the organism used for priming. Enhancement was also found if C. parvum or M. leprae were added to BCG-primed cells and if BCG was added to C. parvum-primed cells. The relevance of the results to the search for a leprosy vaccine is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7007221      PMCID: PMC1458205     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Requirement for accessory cells in the antibody response to T cell-independent antigens in vitro.

Authors:  K C Lee; C Shiozawa; A Shaw; E Diener
Journal:  Eur J Immunol       Date:  1976-01       Impact factor: 5.532

2.  Evidence for separate subpopulations of B cells responding to T-independent and T-dependent immunogens.

Authors:  J J Jennings; M B Rittenberg
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

3.  Activation of lymphoid cells by BCG in vitro.

Authors:  M B Mokyr; M S Mitchell
Journal:  Cell Immunol       Date:  1975-02       Impact factor: 4.868

Review 4.  BCG in tumor immunotherapy.

Authors:  R W Baldwin; M V Pimm
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

5.  Suppressed or enhanced antibody responses in vitro after BCG treatment of mice: importance of BCG viability.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

6.  Active suppression masks an underlying enhancement of antibody production in vitro by spleen cells from BCG-infected mice.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

7.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

8.  Infection with Bacillus Calmette-Guérin activates murine thymus-independent (B) lymphocytes.

Authors:  B M Sultzer
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

9.  Phagosome/lysosome fusion: a possible prerequisite for the enhancement of antibody responses in vitro by BCG, Mycobacterium leprae and Corynebacterium parvum.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Parasite Immunol       Date:  1979       Impact factor: 2.280

10.  Polysaccharides of Mycobacterium bovis Ushi 10, Mycobacterium smegmatis, Mycobacterium phlei, and Atypical Mycobacterium P1.

Authors:  I Azuma; M Ajisaka; Y Yamamura
Journal:  Infect Immun       Date:  1970-09       Impact factor: 3.441

View more
  1 in total

1.  SDS-PAGE analysis of M. leprae protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos.

Authors:  A K Chakrabarty; M A Maire; P H Lambert
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.